NASDAQ · Drug Manufacturers - Specialty & Generic

SUPN (SUPN) Stock

$47.64 +1.88% NASDAQ: SUPN Healthcare

Valuation

MetricValue
Price$47.64
Market Cap$2.77B
P/E Ratio-71.07
P/B Ratio2.64
P/S Ratio3.61
EPS (TTM)$-0.68
52-Week High$59.68
52-Week Low$30.83
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-3.67%
ROA-2.68%
ROCE-3.48%
Gross Margin-5.15%
Operating Margin-5.15%
Net Margin-3.74%
Debt/Equity0.04
Current Ratio1.91

Annual Financials (USD)

Metric20212022202320242025
Revenue$580.0M$667.0M$608.0M$662.0M$719.0M
Operating Profit$86.0M$46.0M$-5.0M$82.0M$-37.0M
Net Profit$53.0M$61.0M$1.0M$74.0M$-39.0M
EPS$0.98$1.04$0.02$1.32$-0.68
Op Margin14.8%6.9%-0.9%12.3%-5.1%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$1.7B$1.7B$1.3B$1.4B$1.5B
Total Liabilities$873.0M$816.0M$356.0M$332.0M$391.0M
Cash$203.0M$93.0M$75.0M$69.0M$128.0M
Borrowings$427.0M$445.0M$42.0M$34.0M$41.0M

Latest News

Supernus Pharmaceuticals to Announce Second Quarter 2026 Financial Results and Host Conference Call on August 4, 2026 GlobeNewswire · Jul 22, 2026 SUPN: Raising target price to $45.00 Argus Research · Jul 22, 2026 1 Cash-Producing Stock on Our Buy List and 2 That Underwhelm StockStory · Jul 16, 2026 1 Growth Stock to Stash and 2 We Turn Down StockStory · Jul 15, 2026 Supernus Celebrates Five-Year Anniversary of Qelbree® FDA Approval, Continuing to Deliver on Real-World Experience in ADHD GlobeNewswire · Jul 14, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$127.0M$117.0M$111.0M$172.0M$47.0M
Investing Cash Flow$-84.0M$-217.0M$268.0M$-191.0M$3.0M
Financing Cash Flow$0$-23.0M$-2.0M$-3.0M$-28.0M
Net Cash Flow$-85.0M$-110.0M$-18.0M$-6.0M$61.0M
Free Cash Flow$125.0M$116.0M$111.0M$171.0M$46.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA49.42
FCF Yield2.93%
Quick Ratio1.72
Interest Coverage—
Return 1Y43.68%
Return 3Y53.35%
Return 5Y72.13%

Ownership

Insiders Held4.46%
Institutions Held102.87%
Institutions Float Held107.67%
Institutional HolderSharesReport Date
Blackrock Inc.8,797,2542026-03-31
Millennium Management Llc3,315,9732026-03-31
Vanguard Portfolio Management LLC3,238,6932026-03-31
Vanguard Capital Management LLC2,467,2152026-03-31
Dimensional Fund Advisors LP2,307,0302026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AMRXAmneal Pharmaceuticals, Inc. $18.01 +0.47% 47.29 $5.75B 0.00%
BHCBausch Health Companies Inc. $4.58 +3.27% -1.38 $1.71B 0.00%
CGON $72.17 -1.84% -26.72 $6.37B 0.00%
CNTACentessa Pharmaceuticals plc $40.50 +0.00% -22.75 $6.27B 0.00%
GRAL $63.44 -1.52% -5.46 $2.72B 0.00%

About SUPN

SUPN stock trades at $47.64 with a market capitalization of $2.77B. The stock is valued at a price-to-earnings (P/E) ratio of -71.07, price-to-book of 2.64, price-to-sales of 3.61. Over the past 52 weeks the stock has ranged between $30.83 and $59.68, and currently trades 20.2% below its 52-week high.

On profitability, SUPN generates a return on equity (ROE) of -3.67%, return on capital employed of -3.48%, an operating margin of -5.15%, a net profit margin of -3.74%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides